Jth journal

The senior author on the paper, that is the Principal Investigator of the lab that enabled the research, was Dr Roger Preston. By understanding how blood proteins impact inflamed cells like those found in diseased tissue, Dr Preston aims to design better targeted therapies. Investigating how potential drug candidates like these affect cell inflammation is a first jth journal vital step in our understanding of any disease. Necessary cookies are absolutely essential for the website to function properly, jth journal.

They also evaluate their peripartum outcomes compared to control data on pregnant women in Japan. Read more. Most recent articles RSS. View all articles. Authors: Massimo Franchini. Most accessed articles RSS. Mark M.

Jth journal

Background: The risk of recurrence after a venous thromboembolism VTE related to estrogen-containing contraceptives is a key driver to guide anticoagulant treatment decisions. Objective: To estimate the incidence rate of recurrent VTE after discontinuation of anticoagulant treatment in women with a first episode of VTE related to estrogen-containing contraceptives. Recurrence rates per patient-years were pooled using Knapp-Hartung random-effects meta-analysis. Results: A total of 4, studies were identified, of which 14 were included. The pooled recurrence rate was 1. Recurrence rates per patient-years were 2. Conclusion: Among women with VTE associated with estrogen-containing contraceptives, the risk of recurrence after stopping anticoagulation is low, which favors short-term anticoagulation. Large prospective studies on VTE recurrence rates and risk factors after stopping short-term anticoagulants are needed. Keywords: contraceptive agents; estrogens; systematic review; thrombosis; women. Abstract Background: The risk of recurrence after a venous thromboembolism VTE related to estrogen-containing contraceptives is a key driver to guide anticoagulant treatment decisions. Publication types Meta-Analysis Systematic Review.

Content type: Review 1 March

You have been directed to this page because your browser does not meet our minimum requirements. Please use the links and instructions below to make changes, and try visiting the site again. Please also verify the web address entered in your browser's address bar. You can be directed to this page if there is an apostrophe ' or a quotation mark " appended to the end of a ScholarOne Manuscripts web address. We have detected that the browser you are using is unknown. ScholarOne Manuscripts does not support this browser at this time. Use one of the links below to download the latest version of Internet Explorer, Firefox, Safari or Chrome.

Journal of Thrombosis and Thrombolysis is a resource for those involved in the treatment and clinical investigation of thrombotic disorders involving the cardiovascular and cerebrovascular systems. Focuses on pathobiology of thrombosis and vascular disorders and the use of anticoagulants, platelet antagonists, cell-based therapies and interventions in scientific investigation, clinical-translational research, population science and patient care. Publishes original work emphasizing the interface between fundamental scientific principles and clinical investigation and is a platform for translational research, drug development, clinical trials, new drugs and devices, and patient-directed applications. Seeks orignal manuscripts related to cardiovascular disease, laboratory investigation, pharmacogenetics, clinical research, global health, population science, and epidemiology and state-of-the-art reviews and position papers. Volume 57, Issue 2. While currently available medications greatly reduce ischemic and thromboembolic risk in a number of conditions, ranging from venous thromboembolism to coronary artery disease, myocardial infarction and stroke, these agents have limitations. These include a residual ischemic risk despite current optimal medications in some individuals, delayed onset of action in others, whilst yet others may experience bleeding complications. These factors contribute significantly to mortality and morbidity. These include, among others, intravenous and subcutaneous antiplatelet medications, and novel anticoagulants including those targeting factor XI and factor XII.

Jth journal

The Journal of Thrombosis and Haemostasis is a monthly peer-reviewed medical journal covering research on thrombosis and hematology in general. It is an official journal of the International Society on Thrombosis and Haemostasis. According to the Journal Citation Reports , the journal has a impact factor of This article about a medical journal is a stub. You can help Wikipedia by expanding it.

Can ramis manacor

Check the Enable JavaScript checkbox. The data collected including the number visitors, the source where they have come from, and the pages viisted in an anonymous form. Click OK. Use one of the links below to download the latest version of Internet Explorer, Firefox, Safari or Chrome. Thrombosis Journal is an open-access journal that publishes original articles on aspects of clinical and basic research, new methodology, case reports and reviews in the areas of thrombosis. Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors. Background: The risk of recurrence after a venous thromboembolism VTE related to estrogen-containing contraceptives is a key driver to guide anticoagulant treatment decisions. Objectives: Here, we investigated the specific receptors and signaling pathways required for platelet function in TEG using genetic and pharmacologic inhibition of platelet proteins in mouse and human blood samples. If you are using Chrome and would like to enable cookies follow these instructions: Click the Chrome menu icon in the top right of the browser. Skip to main content. Relaunch your browser. Most accessed articles RSS.

.

Annual Journal Metrics Citation Impact 3. Click Options. We have detected that your cookies are not enabled. Wildberger, Sander M. Lack of alternatives to colonoscopy limits care of patients unable to complete bowel preparation Tala Al-Saghir. The cookie is used to calculate visitor, session, camapign data and keep track of site usage for the site's analytics report. However you may visit Cookie Settings to provide a controlled consent. We define clinical decision sciences as a holistic examination of how clinical decisions are made. Event News Show All. The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. Content type: Review 12 September Content type: Review 3 July Skip to main content. I would very much like to thank and acknowledge the many years at the helm by my predecessor Prof Hugo Ten Cate.